Insider Buying: NeuroSense Therapeutics (NASDAQ:NRSN) CFO Purchases $200,000.00 in Stock

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) CFO Or Eisenberg purchased 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The stock was purchased at an average price of $0.80 per share, for a total transaction of $200,000.00. Following the acquisition, the chief financial officer owned 1,504,050 shares of the company’s stock, valued at $1,203,240. The trade was a 19.94% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

NeuroSense Therapeutics Stock Performance

Shares of NASDAQ:NRSN opened at $0.80 on Friday. The stock has a market capitalization of $26.20 million, a P/E ratio of -1.49 and a beta of 1.56. NeuroSense Therapeutics Ltd. has a 1-year low of $0.63 and a 1-year high of $2.52. The business has a 50-day moving average price of $0.78 and a two-hundred day moving average price of $0.85.

Hedge Funds Weigh In On NeuroSense Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in NRSN. Squarepoint Ops LLC lifted its position in NeuroSense Therapeutics by 91.0% in the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after acquiring an additional 45,450 shares in the last quarter. Jane Street Group LLC acquired a new position in NeuroSense Therapeutics in the 2nd quarter worth $54,000. Two Sigma Investments LP bought a new position in NeuroSense Therapeutics during the 3rd quarter worth about $26,000. Finally, Yorkville Advisors Global LP bought a new position in NeuroSense Therapeutics during the 4th quarter worth about $77,000. 1.04% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. D. Boral Capital restated a “buy” rating and issued a $14.00 price objective on shares of NeuroSense Therapeutics in a report on Wednesday, April 8th. Roth Mkm initiated coverage on shares of NeuroSense Therapeutics in a report on Tuesday, March 10th. They set a “buy” rating and a $3.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NeuroSense Therapeutics in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $8.50.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.